Hyperlipidemia, hyperlipoproteinemia or dyslipidemia is the presence of elevated or abnormal levels of lipids and / or lipoproteins in the blood. Lipid and lipoprotein abnormalities are extremely common in the general population and are regarded as a highly modifiable risk factor for cardiovascular disease due to the influence of cholesterol, one of the most clinically relevant lipid substances in atheroscterosis.
 
Aim of the work:
This study aimed to evaluate the possible treatment and protective effect of  triphala on hyperlipidemic rats.
 
Material and methods:
Six groups (5rat/group) of female albino rats (Rattus albinus) were used. The 1st group used as control, in the 2^nd group hyperlipidemia (25% fat & 2% cholesterol) was induced for 3 weeks only then sacrified , the 3^rd group was hyperlipidemic rats for 3 weeks then left for other  3 weeks without any additional treatment as a recovery period, the 4^th group served as hyperlipidemic group for 3 weeks then treated with triphala for  another 3 weeks (25 mg/100 gm b. wt.), the 5^th group was hyperlipidemic (25% fat & 2% cholesterol) for 6 weeks and the 6^th group served as hyperlipidemic rats for 6 weeks, and at the same time given triphala (25 mg/100 gm b. wt.) by oral administration.
 
Results:
The biochemical parameters showed highly significant increase in the body weight, serum glucose, ASAT, ALAT, GGT, LDH, total protein, albumin and total lipids in liver .Many histopathological and histochemical changes were detected in liver tissue of the hyperlipidemic rats. Meanwhile, the treatment with triphala ameliorated the biochemical parameters, histological and histochemical results.
 
Conclusion:
It is recommended to use triphala in diets for hyperlipidemic patients or those people who have hyperlipidemic family history.